Welcome.
Are you a healthcare professional?

This website contains promotional information for Chiesi's respiratory products, and is intended solely for UK healthcare professionals. Please confirm below, or go back to the home page.

I am a UK healthcare professional No, take me back
UK-RES-2101606 August 2021

You are now leaving Chiesi's website

By clicking this link, you will be taken to a website that is not owned or controlled by Chiesi. Chiesi is not responsible for the content provided on that site.

Continue
Go back

UK-RES-2101574 August 2021

INTENDED FOR UK HEALTHCARE PROFESSIONALS ONLY
Trimbow® for Moderate to Severe COPD Overview

Dosing & Device

Costing

Evidence

Prescribing Information

General Resources

Request a Representative

Think triple (ICS/LABA/LAMA),
think Trimbow®

The only extrafine formulation ICS/LABA/LAMA combination1-3

Designed to reach the large and small airways1,2,4

The only ICS/LABA/LAMA combination available in both a pMDI and NEXThaler (DPI) for the maintenance treatment of adult patients with moderate to severe COPD who require triple therapy1–3

Trimbow pMDI 87/5/9 and NEXThaler 88/5/9 are indicated for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist or a combination of a long-acting β2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.1 of the SPC).1,2

Trimbow® Device

Each dose contains three molecules:1,2

  • Beclometasone
  • Formoterol
  • Glycopyrronium
Trimbow is a maintenance treatment for your adult patients with moderate to severe COPD not adequately treated with ICS/LABA or LABA/LAMA who require triple therapy1,2

Extrafine formulation like Fostair® (beclometasone/formoterol)1,2,5,6

Choice of pMDI or NEXThaler device to meet your patients’ needs1,2

Trimbow pMDI 87/5/9 demonstrated reduction in moderate to severe exacerbations vs.:1

  • LAMA (Spiriva® HandiHaler®)7
  • ICS/LABA (Fostair pMDI 100/6) – secondary endpoint8
  • LABA/LAMA (Ultibro® Breezhaler®)9
Co‑primary endpoints of TRILOGY: Superiority of Trimbow pMDI vs. Fostair pMDI 100/6 was met in change from baseline in pre‑dose morning FEV1 (p<0.001), change from baseline in 2‑h post‑dose FEV1 (p<0.001), but unmet for TDI focal score (p=0.160), all assessed at week 26 (N=1,368).8

Trimbow is not licensed as a step-up treatment for COPD patients on a LAMA only.

Trimbow pMDI 87/5/9 and NEXThaler 88/5/9 are indicated for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist or a combination of a long-acting β2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.1 of the SPC).1,2


For additional information to share with your patients who have been prescribed Trimbow, please visit our Trimbow patient and carer site.


Fostair 100/6 is indicated for symptomatic treatment of adult patients with severe COPD (FEV1 <50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.5,6


COPD: chronic obstructive pulmonary disease; DPI: dry powder inhaler; FEV1: forced expiratory volume in one second; ICS: inhaled corticosteroid; LABA: long-acting β2-agonist; LAMA: long-acting muscarinic antagonist; N: number of patients in the intention-to-treat population; pMDI: pressurised metered dose inhaler; SPC: Summary of Product Characteristics; TDI: transition dyspnea index.

References: 

  1. Trimbow pMDI 87/5/9 Summary of Product Characteristics. Chiesi Limited.
  2. Trimbow NEXThaler 88/5/9 Summary of Product Characteristics. Chiesi Limited.
  3. MIMS online. 2021. Available at: https://www.mims.co.uk/.
  4. Singh D. Tuberc Respir Dis. 2017; 80: 317 -324.
  5. Fostair pMDI 100/6 Summary of Product Characteristics, Chiesi Limited.
  6. Fostair NEXThaler 100/6 Summary of Product Characteristics. Chiesi Limited.
  7. Vestbo J, et al. Lancet. 2017; 389: 1919-1929.
  8. Singh D, et al. Lancet. 2016; 388: 963-973.
  9. Papi A, et al. Lancet. 2018; 391: 1076-1084.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Chiesi Limited on 0800 0092329 (UK) or PV.UK@Chiesi.com.